Structural MR and amyloid PET imaging have been proposed by the National Institute on Aging as methods to subdivide preclinical Alzheimer Disease (AD) into discrete stages of (1) amyloidosis, followed by (2) amyloidosis plus neurodegeneration, both of which precede (3) subtle cognitive decline, followed by the clinical progression to mild cognitive impairment (MCI) and AD dementia. The HASD Imaging Core will provide MR and PET support to the HASD Projects to test how these proposed stages relate to the transition for normal to impaired cognitive performance (Project 1), sleep disturbance (Project 2), and genetic analyses (Project 3). The following Specific Aims will be pursued: I. Combined PET-MR scanning for brain structure, function, and amyloid pathology. For the entire combined HASD and ADRC cohorts, we will perform brain MRI and florbetapir F18 (AV45) amyloid imaging every three years (200 participants/year). II. Provide data processing for these imaging tests, to include (2a) matched regional volumes, thicknesses, and quantitative PET analyses, (2b) quantitative individual longitudinal participant reports compared normative values generated by the cohort, and (2c) grouped regional reports based on classifications derived from the Projects and Cores. III. Generate an online accessible resource containing source imaging (DICOM), processed imaging, and clinical and biomarker characterization to facilitate data sharing outside of our institution, including contributions to the private-public partnership developed by JC Morris, HASD PI, and T. Benzinger, HASD Imaging Core Leader, with Avid/Lilly. This partnership allows funding for longitudinal MR and amyloid PET imaging for the entire cohort.
Core E: Imaging Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.
|Lucey, Brendan P; Mawuenyega, Kwasi G; Patterson, Bruce W et al. (2016) Associations Between Î²-Amyloid Kinetics and the Î²-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol :|
|Esparza, Thomas J; Wildburger, Norelle C; Jiang, Hao et al. (2016) Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Sci Rep 6:38187|
|McKee, Ann C; Cairns, Nigel J; Dickson, Dennis W et al. (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 131:75-86|
|Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61|
|Jin, Sheng Chih; Benitez, Bruno A; Deming, Yuetiva et al. (2016) Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. Methods Mol Biol 1303:299-314|
|Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43|
|Van Schependom, Jeroen; Jain, Saurabh; Cambron, Melissa et al. (2016) Reliability of measuring regional callosal atrophy in neurodegenerative diseases. Neuroimage Clin 12:825-831|
|Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50|
|Su, Yi; Rubin, Brian B; McConathy, Jonathan et al. (2016) Impact of MR-Based Attenuation Correction on Neurologic PET Studies. J Nucl Med 57:913-7|
|Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9|
Showing the most recent 10 out of 756 publications